查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070561

泌尿生殖系統藥物市場：規模、佔有率、成長、全球產業分析、區域洞察，2026-2034年預測

Genitourinary Drugs Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

泌尿生殖系統藥物市場成長要素

2025年全球泌尿生殖系統藥物市場規模為287億美元，預計將從2026年的301億美元成長到2034年的444億美元，預測期內年複合成長率為4.98%。北美地區在2025年佔據市場主導地位，市場佔有率達38.08%，這得益於其較高的診斷率、先進的醫療基礎設施以及創新治療方法的廣泛普及。

泌尿生殖系統藥物用於治療影響泌尿器官系統和生殖系統的疾病，包括良性前列腺增生（BPH）、勃起功能障礙、膀胱過動症（OAB）、尿道感染（UTI）、攝護腺癌、膀胱癌和尿失禁。這些疾病盛行率的不斷上升，加上人口老化和人們健康意識的增強，持續推動全球市場的擴張。

主要市場趨勢

泌尿系統腫瘤專科藥物的擴張

影響泌尿生殖系統藥物市場的最重要趨勢之一是膀胱癌、腎臟癌和前列腺癌專科藥物的日益普及。製藥公司正大力投資免疫療法、抗體藥物複合體（ADC）和局部給藥系統，目的是提高存活率和治療效果。

2026年3月，Johnson & Johnson宣布其用於臨床實驗膀胱癌的膀胱內給藥系統Erda-iDRS取得了積極成果。該系統使用erdafitinib。此類創新凸顯了癌症治療產業正朝著更專業化和標靶化的方向發展。

市場促進因素

泌尿器官系統和生殖系統疾病盛行率增加

泌尿系統和生殖系統疾病發生率的不斷上升仍然是推動成長要素。良性前列腺增生（BPH）、勃起功能障礙、前列腺癌和膀胱疾病等病症越來越常見，尤其是在老年人群中。

2025年 6月，Bayer AG獲得 FDA 批准，其藥物NUBEQA (darolutamide)用於治療轉移性激素敏感性前列腺癌，擴大了治療途徑，並進一步增加了對先進泌尿生殖系統治療方法的需求。

市場限制因素

副作用和藥物耐受性差

許多泌尿生殖系統藥物都有一些副作用，例如頭暈、便秘、口乾、認知障礙和性功能障礙。這些副作用常導致患者用藥依從性降低，長期治療維持率下降。

因此，對於目的是持續增加處方箋數量的製藥公司而言，治療中斷率仍然是個挑戰。

市場機會

新型藥物遞送技術的開發

創新的藥物遞送平台為市場創造巨大的機會。緩釋製劑和膀胱內給藥療法在提高病灶部位藥物暴露的同時，也提升了病患的便利性。

例如，UroGen Pharma 的UGN-102 採用 RTGel 緩釋技術治療非肌肉浸潤性膀胱癌，這表明先進的給藥系統可以改善臨床結果並擴大治療方法的範圍。

市場挑戰

定價和保險償付問題

尤其是在腫瘤領域，先進的治療方法往往價格昂貴，這限制了患者獲得治療的機會。保險償付核准延遲和資金籌措也是這些治療方法廣泛應用的障礙。

醫療保健系統正日益面臨平衡成本效益與獲得創新療法之間的挑戰，尤其是在前列腺癌和膀胱癌的治療方面。

區域分析

北美洲

北美仍然是最大的區域市場，到2025年達到 109.3億美元。強大的醫療保健基礎設施、較高的疾病意識以及創新治療方法的快速普及繼續支持著該地區的成長。

歐洲

在歐洲，由於人口老化和慢性泌尿生殖系統疾病負擔加重，經濟預計將維持穩定成長。

亞太地區

亞太地區崛起為高成長地區，這得益於中國、印度和日本等國家醫療保健服務的改善、醫療保健支出的增加以及患者人數的擴大。

拉丁美洲、中東和非洲

預計這些地區將經歷適度成長，這得益於人們意識的提高、醫療保健的現代化以及治療選擇範圍的擴大。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場挑戰
  • 市場趨勢

第4章 主要考察

  • 主要泌尿生殖系統疾病的盛行率：依主要地區和國家分類
  • 新產品發布：依主要公司分類
  • 大型公司管道分析
  • 主要地區和國家的監管情況概述
  • 產業重大發展動態（合併、收購、合作、新產品發布等）

第5章 2021-2034年全球泌尿生殖系統藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：依藥物類別分類
    • 雄性激素受體通路抑制劑
    • GnRH促效劑/GnRH拮抗劑
    • PDE5抑制劑
    • α受體阻斷劑
    • 抗毒蕈鹼藥物/抗膽鹼能藥物
    • BETA-3腎上腺素受體促效劑
    • 其他
  • 市場分析、洞察與預測：依疾病適應症分類
    • 攝護腺癌
    • 良性攝護腺增生（BPH）
    • 勃起功能障礙
    • 膀胱過動症（OAB）
    • 尿道感染（UTI）
    • 膀胱癌/尿路上皮癌
    • 其他
  • 市場分析、洞察與預測：依年齡層別分類
    • 兒童
    • 成人
    • 老年人
  • 市場分析、洞察與預測：依類型
    • 品牌
    • 學名藥
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 陰道內部
    • 注射/腸外給藥
    • 外用/經皮給藥
    • 其他
  • 市場分析、洞察與預測：依性別分類
    • 男性
    • 女性
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
    • 專科藥房
  • 分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美泌尿生殖系統藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲泌尿生殖系統藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太泌尿生殖系統藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章 拉丁美洲泌尿生殖系統藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 2021-2034年中東和非洲泌尿生殖系統藥物市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Bayer AG
    • AstraZeneca PLC
    • Sumitomo Pharma Co., Ltd.
    • Organon & Co.
    • Ferring Pharmaceuticals
    • Endo, Inc.
Product Code: FBI116092

Growth Factors of genitourinary drugs Market

The global genitourinary drugs market size was valued at USD 28.70 billion in 2025 and is projected to grow from USD 30.10 billion in 2026 to USD 44.40 billion by 2034, exhibiting a CAGR of 4.98% during the forecast period. North America dominated the market with a 38.08% share in 2025, supported by high diagnosis rates, advanced healthcare infrastructure, and widespread access to innovative therapies.

Genitourinary drugs are used to treat disorders affecting the urinary and reproductive systems, including benign prostatic hyperplasia (BPH), erectile dysfunction, overactive bladder (OAB), urinary tract infections (UTIs), prostate cancer, bladder cancer, and urinary incontinence. Growing prevalence of these disorders, combined with an aging population and increasing healthcare awareness, continues to drive market expansion worldwide.

Key Market Trend

Expansion of Specialty Drugs for Urologic Oncology

One of the most significant trends shaping the genitourinary drugs market is the growing adoption of specialty drugs for bladder, kidney, and prostate cancers. Pharmaceutical companies are investing heavily in immunotherapies, antibody-drug conjugates, and localized drug-delivery systems designed to improve survival rates and treatment outcomes.

In March 2026, Johnson & Johnson announced positive results for Erda-iDRS, an investigational intravesical drug-releasing system utilizing erdafitinib for bladder cancer treatment. Such innovations highlight the industry's transition toward more specialized and targeted oncology therapies.

Market Drivers

Rising Prevalence of Urinary and Reproductive Disorders

The increasing incidence of urinary tract disorders and reproductive health conditions remains a primary growth driver. Conditions such as BPH, erectile dysfunction, prostate cancer, and bladder disorders are becoming more common, particularly among aging populations.

In June 2025, Bayer AG received FDA approval for NUBEQA (darolutamide) for metastatic hormone-sensitive prostate cancer, expanding treatment access and reinforcing demand for advanced genitourinary therapies.

Market Restraints

Side Effects and Poor Drug Tolerability

Many genitourinary drugs are associated with adverse effects such as dizziness, constipation, dry mouth, cognitive impairment, and sexual dysfunction. These side effects often reduce patient compliance and long-term treatment adherence.

As a result, treatment discontinuation rates remain a challenge for pharmaceutical companies seeking sustained prescription growth.

Market Opportunities

Development of Novel Drug-Delivery Technologies

Innovative drug-delivery platforms are creating substantial opportunities across the market. Sustained-release formulations and intravesical therapies improve drug exposure at disease sites while enhancing patient convenience.

For example, UroGen Pharma's UGN-102 utilizes RTGel sustained-release technology to treat non-muscle-invasive bladder cancer, demonstrating how advanced delivery systems can improve clinical outcomes and expand treatment adoption.

Market Challenges

Pricing and Reimbursement Issues

Advanced therapies, particularly in oncology, often carry premium pricing that can limit accessibility. Delays in reimbursement approvals and funding restrictions create barriers to widespread adoption.

Healthcare systems increasingly face challenges balancing affordability with access to innovative treatments, especially in prostate and bladder cancer therapies.

Segment Analysis

By Drug Class

The PDE5 inhibitors segment dominated the market in 2025 due to widespread use in erectile dysfunction treatment. Established products and high patient acceptance continue to support segment leadership.

The beta-3 adrenergic agonists segment is expected to register the fastest growth during the forecast period.

By Disease Indication

The Benign Prostatic Hyperplasia (BPH) segment accounted for the largest market share in 2025. Long-term treatment requirements and growing prevalence among aging men contribute significantly to demand.

The bladder/urothelial cancer segment is projected to witness strong growth due to increasing adoption of targeted therapies.

By Age Group

The adult segment held the largest share in 2025 because most genitourinary disorders are diagnosed and treated within adult populations.

By Type

Branded drugs dominated the market owing to their innovative mechanisms, premium pricing, and strong clinical differentiation, particularly in oncology.

By Route of Administration

The oral segment captured the largest share due to ease of administration, patient convenience, and suitability for chronic disease management.

By Gender

The male segment dominated the market because of the high prevalence of prostate cancer, erectile dysfunction, and BPH.

By Distribution Channel

Drug stores and retail pharmacies represented the leading distribution channel due to their accessibility and role in dispensing long-term outpatient therapies.

Regional Analysis

North America

North America remained the leading regional market, reaching USD 10.93 billion in 2025. Strong healthcare infrastructure, high disease awareness, and rapid adoption of innovative treatments continue to support regional growth.

Europe

Europe is expected to experience steady growth due to its aging population and increasing burden of chronic genitourinary disorders.

Asia Pacific

Asia Pacific is emerging as a high-growth region driven by improving healthcare access, rising healthcare expenditures, and expanding patient populations in countries such as China, India, and Japan.

Latin America and Middle East & Africa

These regions are expected to witness moderate growth supported by increasing awareness, healthcare modernization, and expanding access to treatment options.

Competitive Landscape

Major companies operating in the genitourinary drugs market include:

  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bayer AG
  • AstraZeneca PLC
  • Organon & Co.
  • Ferring Pharmaceuticals

These companies are focusing on product innovation, regulatory approvals, strategic partnerships, and oncology-focused research to strengthen their market positions.

Recent Industry Developments

  • March 2026: UroGen Pharma announced progress toward the commercial launch of ZUSDURI for recurrent bladder cancer.
  • February 2026: Organon partnered with Sebela Pharmaceuticals for rights to MIUDELLA, a hormone-free copper IUD.
  • November 2025: Pfizer received FDA approval for PADCEV combined with Keytruda for muscle-invasive bladder cancer treatment.
  • June 2025: Knight Therapeutics partnered with Sumitomo Pharma America to commercialize multiple genitourinary therapies in Canada.
  • March 2025: GSK received FDA approval for Blujepa (gepotidacin) for uncomplicated urinary tract infections.

Conclusion

The global genitourinary drugs market is positioned for steady growth through 2034, supported by rising prevalence of urinary and reproductive disorders, expanding aging populations, and increasing adoption of targeted therapies. Advances in specialty oncology drugs, innovative drug-delivery technologies, and broader treatment accessibility are expected to reshape the competitive landscape. Despite challenges related to drug tolerability, pricing, and reimbursement, ongoing pharmaceutical innovation and growing healthcare investments will continue to create significant opportunities for market participants throughout the forecast period.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Region

By Drug Class * Androgen Receptor Pathway Inhibitors

  • GnRH Agonists/GnRH Antagonists
  • PDE5 Inhibitors
  • Alpha Blockers
  • Antimuscarinics/Anticholinergics
  • Beta-3 Adrenergic Agonists
  • Others

By Disease Indication * Prostate Cancer

  • Benign Prostatic Hyperplasia (BPH)
  • Erectile Dysfunction
  • Overactive Bladder (OAB)
  • Urinary Tract Infections (UTIs)
  • Bladder/Urothelial Cancer
  • Others

By Age Group * Pediatric

  • Adult
  • Geriatric

By Type * Branded

  • Generics

By Route of Administration * Oral

  • Vaginal
  • Injectable/Parenteral
  • Topical/Transdermal
  • Others

By Gender * Male

  • Female

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Genitourinary Disease Indications, By Key Regions/ Countries
  • 4.2. New Product Launches, By Key Players
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview of Regulatory Scenario, By Key Regions/ Countries
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)

5. Global Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Pathway Inhibitors
    • 5.1.2. GnRH Agonists/GnRH Antagonists
    • 5.1.3. PDE5 Inhibitors
    • 5.1.4. Alpha Blockers
    • 5.1.5. Antimuscarinics/Anticholinergics
    • 5.1.6. Beta-3 Adrenergic Agonists
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Prostate Cancer
    • 5.2.2. Benign Prostatic Hyperplasia (BPH)
    • 5.2.3. Erectile Dysfunction
    • 5.2.4. Overactive Bladder (OAB)
    • 5.2.5. Urinary Tract Infections (UTIs)
    • 5.2.6. Bladder/Urothelial Cancer
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adult
    • 5.3.3. Geriatric
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Generics
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Vaginal
    • 5.5.3. Injectable/Parenteral
    • 5.5.4. Topical/Transdermal
    • 5.5.5. Others
  • 5.6. Market Analysis, Insights and Forecast - By Gender
    • 5.6.1. Male
    • 5.6.2. Female
  • 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.7.1. Hospital Pharmacies
    • 5.7.2. Drug Stores & Retail Pharmacies
    • 5.7.3. Online Pharmacies
    • 5.7.4. Specialty Pharmacies
  • 5.8. Market Analysis, Insights and Forecast - Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. Asia Pacific
    • 5.8.4. Latin America
    • 5.8.5. Middle East & Africa

6. North America Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Pathway Inhibitors
    • 6.1.2. GnRH Agonists/GnRH Antagonists
    • 6.1.3. PDE5 Inhibitors
    • 6.1.4. Alpha Blockers
    • 6.1.5. Antimuscarinics/Anticholinergics
    • 6.1.6. Beta-3 Adrenergic Agonists
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Prostate Cancer
    • 6.2.2. Benign Prostatic Hyperplasia (BPH)
    • 6.2.3. Erectile Dysfunction
    • 6.2.4. Overactive Bladder (OAB)
    • 6.2.5. Urinary Tract Infections (UTIs)
    • 6.2.6. Bladder/Urothelial Cancer
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adult
    • 6.3.3. Geriatric
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Generics
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Vaginal
    • 6.5.3. Injectable/Parenteral
    • 6.5.4. Topical/Transdermal
    • 6.5.5. Others
  • 6.6. Market Analysis, Insights and Forecast - By Gender
    • 6.6.1. Male
    • 6.6.2. Female
  • 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.7.1. Hospital Pharmacies
    • 6.7.2. Drug Stores & Retail Pharmacies
    • 6.7.3. Online Pharmacies
    • 6.7.4. Specialty Pharmacies
  • 6.8. Market Analysis, Insights and Forecast - By Country
    • 6.8.1. U.S.
    • 6.8.2. Canada

7. Europe Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Pathway Inhibitors
    • 7.1.2. GnRH Agonists/GnRH Antagonists
    • 7.1.3. PDE5 Inhibitors
    • 7.1.4. Alpha Blockers
    • 7.1.5. Antimuscarinics/Anticholinergics
    • 7.1.6. Beta-3 Adrenergic Agonists
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Prostate Cancer
    • 7.2.2. Benign Prostatic Hyperplasia (BPH)
    • 7.2.3. Erectile Dysfunction
    • 7.2.4. Overactive Bladder (OAB)
    • 7.2.5. Urinary Tract Infections (UTIs)
    • 7.2.6. Bladder/Urothelial Cancer
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adult
    • 7.3.3. Geriatric
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Generics
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Oral
    • 7.5.2. Vaginal
    • 7.5.3. Injectable/Parenteral
    • 7.5.4. Topical/Transdermal
    • 7.5.5. Others
  • 7.6. Market Analysis, Insights and Forecast - By Gender
    • 7.6.1. Male
    • 7.6.2. Female
  • 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.7.1. Hospital Pharmacies
    • 7.7.2. Drug Stores & Retail Pharmacies
    • 7.7.3. Online Pharmacies
    • 7.7.4. Specialty Pharmacies
  • 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.8.1. U.K.
    • 7.8.2. Germany
    • 7.8.3. France
    • 7.8.4. Italy
    • 7.8.5. Spain
    • 7.8.6. Scandinavia
    • 7.8.7. Rest of Europe

8. Asia Pacific Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Pathway Inhibitors
    • 8.1.2. GnRH Agonists/GnRH Antagonists
    • 8.1.3. PDE5 Inhibitors
    • 8.1.4. Alpha Blockers
    • 8.1.5. Antimuscarinics/Anticholinergics
    • 8.1.6. Beta-3 Adrenergic Agonists
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Prostate Cancer
    • 8.2.2. Benign Prostatic Hyperplasia (BPH)
    • 8.2.3. Erectile Dysfunction
    • 8.2.4. Overactive Bladder (OAB)
    • 8.2.5. Urinary Tract Infections (UTIs)
    • 8.2.6. Bladder/Urothelial Cancer
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adult
    • 8.3.3. Geriatric
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Generics
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Oral
    • 8.5.2. Vaginal
    • 8.5.3. Injectable/Parenteral
    • 8.5.4. Topical/Transdermal
    • 8.5.5. Others
  • 8.6. Market Analysis, Insights and Forecast - By Gender
    • 8.6.1. Male
    • 8.6.2. Female
  • 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.7.1. Hospital Pharmacies
    • 8.7.2. Drug Stores & Retail Pharmacies
    • 8.7.3. Online Pharmacies
    • 8.7.4. Specialty Pharmacies
  • 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.8.1. China
    • 8.8.2. Japan
    • 8.8.3. India
    • 8.8.4. Southeast Asia
    • 8.8.5. Australia
    • 8.8.6. Rest of Asia Pacific

9. Latin America Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Pathway Inhibitors
    • 9.1.2. GnRH Agonists/GnRH Antagonists
    • 9.1.3. PDE5 Inhibitors
    • 9.1.4. Alpha Blockers
    • 9.1.5. Antimuscarinics/Anticholinergics
    • 9.1.6. Beta-3 Adrenergic Agonists
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Prostate Cancer
    • 9.2.2. Benign Prostatic Hyperplasia (BPH)
    • 9.2.3. Erectile Dysfunction
    • 9.2.4. Overactive Bladder (OAB)
    • 9.2.5. Urinary Tract Infections (UTIs)
    • 9.2.6. Bladder/Urothelial Cancer
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adult
    • 9.3.3. Geriatric
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Generics
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Oral
    • 9.5.2. Vaginal
    • 9.5.3. Injectable/Parenteral
    • 9.5.4. Topical/Transdermal
    • 9.5.5. Others
  • 9.6. Market Analysis, Insights and Forecast - By Gender
    • 9.6.1. Male
    • 9.6.2. Female
  • 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Drug Stores & Retail Pharmacies
    • 9.7.3. Online Pharmacies
    • 9.7.4. Specialty Pharmacies
  • 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.8.1. Brazil
    • 9.8.2. Mexico
    • 9.8.3. Rest of Latin America

10. Middle East & Africa Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Pathway Inhibitors
    • 10.1.2. GnRH Agonists/GnRH Antagonists
    • 10.1.3. PDE5 Inhibitors
    • 10.1.4. Alpha Blockers
    • 10.1.5. Antimuscarinics/Anticholinergics
    • 10.1.6. Beta-3 Adrenergic Agonists
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Prostate Cancer
    • 10.2.2. Benign Prostatic Hyperplasia (BPH)
    • 10.2.3. Erectile Dysfunction
    • 10.2.4. Overactive Bladder (OAB)
    • 10.2.5. Urinary Tract Infections (UTIs)
    • 10.2.6. Bladder/Urothelial Cancer
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adult
    • 10.3.3. Geriatric
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Generics
  • 10.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.5.1. Oral
    • 10.5.2. Vaginal
    • 10.5.3. Injectable/Parenteral
    • 10.5.4. Topical/Transdermal
    • 10.5.5. Others
  • 10.6. Market Analysis, Insights and Forecast - By Gender
    • 10.6.1. Male
    • 10.6.2. Female
  • 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Drug Stores & Retail Pharmacies
    • 10.7.3. Online Pharmacies
    • 10.7.4. Specialty Pharmacies
  • 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.8.1. GCC
    • 10.8.2. South Africa
    • 10.8.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Merck & Co., Inc.
    • 11.2.4. Johnson & Johnson
    • 11.2.5. Bayer AG
    • 11.2.6. AstraZeneca PLC
    • 11.2.7. Sumitomo Pharma Co., Ltd.
    • 11.2.8. Organon & Co.
    • 11.2.9. Ferring Pharmaceuticals
    • 11.2.10. Endo, Inc.

List of Tables

  • Figure 1: Global Genitourinary Drugs Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Genitourinary Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Genitourinary Drugs Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Genitourinary Drugs Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Genitourinary Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 6: Global Genitourinary Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Genitourinary Drugs Market Value Share (%), by Gender, 2025 & 2034
  • Figure 8: Global Genitourinary Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 9: Global Genitourinary Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 10: North America Genitourinary Drugs Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 11: North America Genitourinary Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 12: North America Genitourinary Drugs Market Value (USD Billion), by Disease Indication, 2025 & 2034
  • Figure 13: North America Genitourinary Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 14: North America Genitourinary Drugs Market Value (USD Billion), by Age Group, 2025 & 2034
  • Figure 15: North America Genitourinary Drugs Market Value Share (%), by Age Group, 2025
  • Figure 16: North America Genitourinary Drugs Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 17: North America Genitourinary Drugs Market Value Share (%), by Type, 2025
  • Figure 18: North America Genitourinary Drugs Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 19: North America Genitourinary Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 20: North America Genitourinary Drugs Market Value (USD Billion), by Gender, 2025 & 2034
  • Figure 21: North America Genitourinary Drugs Market Value Share (%), by Gender, 2025
  • Figure 22: North America Genitourinary Drugs Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 23: North America Genitourinary Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 24: North America Genitourinary Drugs Market Value (USD Billion), by Country, 2025 & 2034
  • Figure 25: North America Genitourinary Drugs Market Value Share (%), by Country, 2025
  • Figure 26: Europe Genitourinary Drugs Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 27: Europe Genitourinary Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 28: Europe Genitourinary Drugs Market Value (USD Billion), by Disease Indication, 2025 & 2034
  • Figure 29: Europe Genitourinary Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 30: Europe Genitourinary Drugs Market Value (USD Billion), by Age Group, 2025 & 2034
  • Figure 31: Europe Genitourinary Drugs Market Value Share (%), by Age Group, 2025
  • Figure 32: Europe Genitourinary Drugs Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 33: Europe Genitourinary Drugs Market Value Share (%), by Type, 2025
  • Figure 34: Europe Genitourinary Drugs Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 35: Europe Genitourinary Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Europe Genitourinary Drugs Market Value (USD Billion), by Gender, 2025 & 2034
  • Figure 37: Europe Genitourinary Drugs Market Value Share (%), by Gender, 2025
  • Figure 38: Europe Genitourinary Drugs Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 39: Europe Genitourinary Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 40: Europe Genitourinary Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 41: Europe Genitourinary Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 42: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 43: Asia Pacific Genitourinary Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 44: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Disease Indication, 2025 & 2034
  • Figure 45: Asia Pacific Genitourinary Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 46: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Age Group, 2025 & 2034
  • Figure 47: Asia Pacific Genitourinary Drugs Market Value Share (%), by Age Group, 2025
  • Figure 48: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 49: Asia Pacific Genitourinary Drugs Market Value Share (%), by Type, 2025
  • Figure 50: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 51: Asia Pacific Genitourinary Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Gender, 2025 & 2034
  • Figure 53: Asia Pacific Genitourinary Drugs Market Value Share (%), by Gender, 2025
  • Figure 54: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 55: Asia Pacific Genitourinary Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 56: Asia Pacific Genitourinary Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 57: Asia Pacific Genitourinary Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 58: Latin America Genitourinary Drugs Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 59: Latin America Genitourinary Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 60: Latin America Genitourinary Drugs Market Value (USD Billion), by Disease Indication, 2025 & 2034
  • Figure 61: Latin America Genitourinary Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 62: Latin America Genitourinary Drugs Market Value (USD Billion), by Age Group, 2025 & 2034
  • Figure 63: Latin America Genitourinary Drugs Market Value Share (%), by Age Group, 2025
  • Figure 64: Latin America Genitourinary Drugs Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 65: Latin America Genitourinary Drugs Market Value Share (%), by Type, 2025
  • Figure 66: Latin America Genitourinary Drugs Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 67: Latin America Genitourinary Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 68: Latin America Genitourinary Drugs Market Value (USD Billion), by Gender, 2025 & 2034
  • Figure 69: Latin America Genitourinary Drugs Market Value Share (%), by Gender, 2025
  • Figure 70: Latin America Genitourinary Drugs Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 71: Latin America Genitourinary Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 72: Latin America Genitourinary Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 73: Latin America Genitourinary Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 74: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 75: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 76: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Disease Indication, 2025 & 2034
  • Figure 77: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 78: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Age Group, 2025 & 2034
  • Figure 79: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Age Group, 2025
  • Figure 80: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 81: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Type, 2025
  • Figure 82: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 83: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 84: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Gender, 2025 & 2034
  • Figure 85: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Gender, 2025
  • Figure 86: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 87: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 88: Middle East & Africa Genitourinary Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 89: Middle East & Africa Genitourinary Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 90: Global Genitourinary Drugs Market Share (%), by Company, 2025